SEARCH

SEARCH BY CITATION

References

  • 1
    Hunsicker LG, Bennett LE. Design of trials of methods to reduce late renal allograft loss: the price of success. Kidney Int Suppl 1995; 52: S120S123.
  • 2
    Kahan BDfor The Rapamune United States Study Group. Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 2000; 356: 194202.
  • 3
    MacDonald AS for The Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271280.
  • 4
    Oberbauer R for The Rapamune Maintenance Regimen Study Group. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance regimen study. Transplantation 2003; 76: 364370.
  • 5
    Kreis H for The Rapamune Maintenance Regimen Trial. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809817.
  • 6
    Rapamune [package insert]. Philadelphia , PA : Wyeth Laboratories; 2000.
  • 7
    Campistol JM for The Rapamune Maintenance Regimen Study Group (abstract). American Transplant Congress 2004; 683.
  • 8
    2003 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1993–2002. Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation , Rockville , MD ; United Network for Organ Sharing , Richmond , VA ; University Renal Research and Education Association , Ann Arbor , MI .
  • 9
    Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 10
    Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late acute rejection. Am J Transplant 2003; 3: 6873.
  • 11
    Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311318.
  • 12
    Kasiske BL, Andany MA, Hernandez D et al. Comparing methods for monitoring serum creatinine to predict late renal allograft failure. Am J Kidney Dis 2001; 38: 10651073.
  • 13
    Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death following renal transplantation. Transplantation 2003; 75: 12911295.
  • 14
    Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311316.
  • 15
    Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients: clinico-pathological correlations using the Banff schema. Transplantation 1995; 59: 511514.
  • 16
    The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 10291037.
  • 17
    European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391396.
  • 18
    US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999; 34: 296303.
  • 19
    Meier-Kriesche HU, Ojo A, Magee JC et al. African-American renal transplant recipients experience decreased risk of death due to infection: possible implications for immunosuppressive strategies. Transplantation 2000; 70: 375379.
  • 20
    Hricik DE, Anton HA, Knauss TC et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 2002; 74: 189193.
  • 21
    Dickinson DM, Ellison MD, Webb RL. Data sources and structure. Am J Transplant 2003; 3(Suppl. 4): 1328.
  • 22
    Wolfe RA, Webb RL, Dickinson DM et al. Analytical approaches for transplant research. Am J Transplant 2003; 3(Suppl. 4): 103113.